Core Viewpoint - Xianruida Medical-B (06669) experienced a significant stock price increase of over 13% following the release of its interim results, with a current price of HKD 12.42 and a trading volume of HKD 11.01 million [1] Financial Performance - The company reported a revenue of RMB 351 million for the first half of the year, representing a year-on-year increase of 20.1% [1] - Net profit for the same period reached RMB 88.577 million, showing a substantial year-on-year growth of 121.7% [1] Regulatory Approval - Xianruida Medical received registration approval from the National Medical Products Administration of China for its peripheral controllable mechanical release fiber spring ring, which is intended for use in embolization of peripheral vascular aneurysms, arteriovenous malformations, and arteriovenous fistulas [1] - The company plans to initiate marketing activities in China for this product at an appropriate time [1] Strategic Developments - In December 2022, Boston Scientific initiated a takeover bid for Xianruida Medical, offering HKD 20 per share for up to 65% of the company's majority stake, with an estimated transaction value of approximately USD 523 million [1] - In July 2023, both parties signed a cooperation framework agreement and service framework agreement to collaborate in areas such as global commercialization, manufacturing services, and product development [1]
先瑞达医疗-B绩后涨超13% 上半年收入增超20% 纯利同比增长121%